2023 World Conference on Lung Cancer (Posters)-EP13.07. Immune Activation Effect of Different Irradiated Sites and Survival in ES-SCLC Patients Treated with Radioimmunotherapy: A Real-World Analysis

EP13.07. Immune Activation Effect of Different Irradiated Sites and Survival in ES-SCLC Patients Treated with Radioimmunotherapy: A Real-World Analysis - PDF(Slides)

Back to course

Pdf Summary

A real-world analysis examined the immune activation effects of radioimmunotherapy (RIT) at different irradiated sites and the optimal timing of RIT in patients with extensive-stage small cell lung cancer (ES-SCLC). The study found that radiation therapy (RT) to the brain had the strongest activation effect, as indicated by three related indicators. The group that received RT to the brain had the lowest mean rank of delta-NLR/PLR/SII, suggesting a more potent immune activation effect compared to other organs. <br /><br />Additionally, the study found that different treatment stages were associated with step-down 9-month overall survival rates. The results indicate that ES-SCLC patients who received RIT earlier had a higher survival rate. <br /><br />Based on the findings of this real-world study, it is suggested that irradiation to the brain exerts the strongest systemic activation effect. Therefore, the integration of RT should be considered earlier in the era of immunotherapy for ES-SCLC.

Asset Subtitle

Min Wu

Meta Tag

Speaker Min Wu

Topic SCLC & Neuroendocrine Tumors: Relapse & Salvage Therapy

Keywords

immune activation effects

radioimmunotherapy

irradiated sites

extensive-stage small cell lung cancer

brain

delta-NLR

PLR

SII

treatment stages

immunotherapy